Posts for Ticker ‘AMAG’

Top Analyst Downgrades (AMD, FOLD, AMAG, FITB, PLCM, TIVO)

These are this Monday morning’s top early-bird analyst downgrades or cautious research calls from Wall Street firms:

Advanced Micro Devices (AMD) Cut to Market Perform at FBR.
Amicus Therapeutics (FOLD) Cut to Neutral at JPMorgan
AMAG Pharmaceuticals (AMAG) Cut to Hold at Jefferies.
Fifth Third Bancorp (FITB) Cut to Buy from Conviction Buy List at Goldman Sachs.
Polycom (PLCM) Cut to Market Perform at Wells Fargo.
TiVo (TIVO) Started as Neutral at JPMorgan.

You can join our open email distribution list which goes out several times per week for top day trader alerts, analyst upgrades and downgrades, IPO’s, key secondary offerings, guru investor data on Buffett and others, mergers, and more.

JON C. OGG

Posted on: October 5, 2009 – 7:17 am in Analyst Calls, , , , , ,

Top Analyst Upgrades and Downgrades (AMAG, AAPL, BX, JBLU, LAZ, RSH, SF, TLB, TIF, XRX, YHOO)

Bull and Bear ImageThese are the top analyst upgrades, downgrades, and initiations seen from Wall Street early this Thursday morning:

AMAG Pharmaceuticals (NASDAQ: AMAG) Cut to Hold at Citigroup.
Apple Inc. (NASDAQ: AAPL) Raised to Outperform at JMP Securities.
The Blackstone Group (NYSE: BX) Raised to Conviction Buy at Goldman Sachs.
JetBlue (NASDAQ: JBLU) Cut to Neutral at JPMorgan.
Lazard (NYSE: LAZ) Raised to Conviction Buy at Goldman Sachs.
RadioShack (NYSE: RSH) Raised to Overweight at Morgan Stanley.
Stifel Financial (NYSE: SF) Cut to Neutral at Goldman Sachs.
Talbots (NYSE: TLB) was upgraded to Buy at Citi and raised to Neutral at Piper Jaffray.
Tiffany & Co. (NYSE: TIF) Raised to Outperform at Credit Suisse.
Xerox Corp. (NYSE: XRX) Raised to Buy at Brean Murray.
Yahoo! Inc. (NASDAQ: YHOO) Raised to Buy at BofA/Merrill Lynch.

JON C. OGG

Posted on: September 10, 2009 – 8:49 am in Analyst Calls, , , , , , , , , , ,

Day Trader Alerts (IMMR, DROOY, GOLD, AU, AUY, SPPI, AMAG, UBS, CS, OSK, FRPT, NAV, MYGN)

We have provided links through on our day trading alerts page this morning.  Each stock is seeing active trading right before the open and brief explanations and analysis are offered at VSInvestor.com:

You can check each morning at VSInvestor.com for earlier pre-market indications in stocks on the move you might not have seen.

Jon C. Ogg

Posted on: July 1, 2009 – 8:35 am in Trading Alert, , , , , , , , , , , , ,

Top Analyst Upgrades (ALU, AGN, AMAG, EIG, JPM, LOGI. MCD, PALM)

money-stack-image27These are the top analyst upgrades and positive research calls we have seen from Wall Street this Friday morning with about two hours until the market opens:

Alcatel-Lucent (ALU) Raised to Outperform at Baird.
Allergan (AGN) Started as Buy at UBS.
AMAG Pharma (AMAG) Started as Buy at Citigroup.
Employers Holdings (EIG) Raised to Outperform at KBW.
JPMorgan Chase (JPM) Started as Outperform at Baird.
Logitech (LOGI) Raised to Neutral from Underperform at B of A Merrill.
McDonald’s (MCD) Raised to Outperform at Baird.
Palm (PALM) Raised to Outperform at RBC.

JON C. OGG

Posted on: March 13, 2009 – 6:38 am in Analyst Calls, , , , , , ,

24/7 Day Trading Alerts (CROX)(OPTR)(FEED)(NTAP)(AMAG)

R218533_855025

Things are so bad at Crocs (CROX) that it is off nearly 50% down near $1.

Optimer Pharmaceuticals (OPTR) continues to be volatility. Details here..

AgFeed (FEED) is getting crushed.

NetApp (NTAP) is today’s tech winner.

AMAG Pharmaceuticals (AMAG) is making a big run up.

Posted on: November 13, 2008 – 9:33 am in Research, , , , ,

Top Pre-Market Analyst Upgrades (AMAG, ANDE, BAC, BMC, CDNS, CTXS, IPAR, JEF, MDR, MYGN, NUVA, SYMC)

These are some of the top pre-market analyst upgrades we are seeing this Wednesday morning:

  • AMAG Pharmaceuticals (AMAG) Started as Overweight at JPMorgan
  • Andersons (ANDE) Started as Outperform at Oppenheimer
  • Bank of America (BAC) Raised to Market Perform at KBW
  • BMC Software (BMC) Raised to Neutral at JPMorgan
  • Cadence Design Systems (CDNS) Raised to Overweight at JPMorgan
  • Citrix Systems (CTXS) Raised to Overweight at JPMorgan
  • Inter Parfums (IPAR) Raised to Buy at Piper Jaffray
  • Jefferies (JEF) Raised to Market Perform at KBW
  • McDermott International (MDR) Started as Buy at American Tech Research
  • Myriad Genetics (MYGN) Started as Outperform at Oppenheimer
  • NuVasive (NUVA) Started as Overweight as JPMorgan
  • Symantec (SYMC) Raised to Overweight at JPMorgan

Jon C. Ogg
October 8, 2008

Posted on: October 8, 2008 – 6:43 am in Analyst Calls, , , , , , , , , , , ,

Biotech Business Daily (AMAG, CEGE, IMCL, XOMA, TRCA)

AMAG Pharmaceuticals (NASDAQ: AMAG) has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI) beginning May 19, 2008. AMAG shares up $1.26 at $39.85. The 52-week range is $38.16 to $72.95.

Cell Genesys (NASDAQ: CEGE) offered 7.1 shares for $30 million in gross proceeds to a single institutional investor at $4.22 per share to finance product development and general corporate purposes. Shares are down 6% to $42.12. The 52-week is $30.34 to $49.18.

Imclone Systems Inc. (NASDAQ: IMCL) is down almost 5% after a downgrade by Morgan Stanley, citing belief that Erbitux will fail to reach expectations. Shares are trading at $42.31 in mid-day trading. The 52-week range is $30.34 to $49.18.

XOMA Ltd. (NASDAQ: XOMA) down over 8% after reporting larger than expected first quarter losses. They showed a loss of $14.2 million and revenues of $12.1 million, failing to hit estimates by Thomson of $16.4 million. Shares trading at $2.12. The 52-week range is $1.96 to $4.39.

Tercica Inc. (NASDAQ: TRCA) up almost 7% today in anticipation of positive first quarter earnings to be announced after market close. Shares trading at $4.77on a 52-week range of $4.30 to $8.11.

Rachel Lopez
May 12, 2008

Posted on: May 12, 2008 – 1:21 pm in Biotech, , , , ,

Cramer Speculates on Dialysis Drug (AMAG, XCR)

On tonight’s MAD MONEY on CNBC, Jim Cramer said he had a speculative biotech stock.  His pick in the sector is AMAG Pharmaceuticals, Inc. (AMAG) because of its soon to be approved  ferumoxytol, a newer and better intravenous iron treatment for kidney disease patients on dialysis.    Cramer thinks there are many reasons to like this one:

  • ferumoxytol should be approved later in the year;
  • he thinks a secondary has put pressure on it, although that gives it more cash to stabilize the stock;
  • has its own strong sales force;
  • was given an untimely and unwarranted analyst downgrade;
  • will perform better than existing drugs on the market;
  • a competing biotech drug received negative FDA comments on safety, yet that isn’t AMAG’s issue; and he thinks this can expand the market from $400 million annually to much higher.

We recently covered a speculative portable dialysis device maker (in prototype and development stage) on our "10 Stocks Under $10" called Xcorporeal, Inc. (AMEX: XCR) which has risen in the last two weeks since being included.  We have also reviewed some of the lower-tier dialysis names for this as well.

We would note that this AMAG traded at $56.00 after an upgrade just in early February and shares closed under $40.00 Friday.

Jon C. Ogg
March 28, 2008

Jon Ogg produces the Special Situation Investing Newsletter and he can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: March 28, 2008 – 5:51 pm in Biotech, Cramer, ,

Biotech News Day (February 4, 2008) (AMAG, AOB, AMGN, CELG, MNTA, OMRI, SVA, STEM)

Below are some of the top issues affecting biotech shares today:

  • AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company developing iron compounds to treat anemia, saw shares rise 4% to $56.00 after brokerage firm Robert W. Baird initiated coverage with an OUTPERFORM rating.
  • American Oriental Bioengineering Inc. (NYSE:AOB) shares are down almost 7% at mid-day with relative high volume trading to $9.50 on no real news.
  • Amgen Inc. (NASDAQ:AMGN) stock shows no reaction to deal with Japanese drug giant Takeda Pharmaceutical. Takeda is to purchase Amgen’s Japanese unit for up to $902 million plus royalties on sales in exchange for access to 13 of Amgen’s new drugs. Amgen hopes this will curb costs and provide cash as their high-selling anemia drug sales slow due to safety issues. 
  • Celgene Corporation (NASDAQ:CELG) shares are down $1.76 to $57.94 at mid-day. Although earnings reported last Thursday met Wall Street expectations, the outlook for the success of its multiple myeloma cancer treatment, Revlimid, is mixed. Today, the company released Phase II data and news for its psoriasis drug CC-10004. The recent study showed positive results and the company announced plans to increase dosages. 
  • Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) shares continued to take a beating after they announced their earnings release date this morning. They had a rough quarter after the FDA rejected their genetic blood-thinner in November, losing about 60% of its share price. Shares are down $0.37 to $7.54 at mid-day. 
  • Omrix Biopharmaceuticals, Inc. (NASDAQ:OMRI) shares are slightly recovering today after a sharp plummet over the last 2 weeks following the FDA approval for competitor ZymoGenetics’ (ZGEN) Recothrom, that will compete with Omrix’s Evithrom in the thrombin drug market. Omrix announced last Friday that their CFO is resigning. Shares are up 4% to $21.27 on relatively heavy trading volume at mid-day. A month ago, shares were trading at over $30. 
  • Sinovac Biotech Ltd. (AMEX:SVA), the Chinese vaccine provider, has shares up over 5% to $4.11 at mid-day after Sinovec announced the private placement of 2,500,000 common shares for $9.75 million to Sansar Capital Management. 
  • StemCells Inc. (NASDAQ:STEM) stock continued to rise after news last Thursday that it plans to collaborate with Casey Eye Institute to study their leading product candidate, HuCNS-SC, a probable treatment for retinal degeneration which is a leading cause of blindness. Shares are up over 15% at mid-day to $1.77.

Rachel Lopez
February 4, 2008

Posted on: February 4, 2008 – 2:41 pm in Biotech, , , , , , , ,